Greenberg Traurig Advising JATT II on Go-Public Merger with Talawar

NEW YORK - June 30, 2026 - Global law firm Greenberg Traurig, LLP is advising JATT II Acquisition Corp., a special purpose acquisition company focused on building the next wave of life sciences companies, on the signing of a definitive business combination agreement with Talawar TX Inc., a biotechnology company developing potentially best-in-class bispecific antibodies that pair independent immunology & inflammatory disease drivers in a single therapy.

The business combination is expected to close in the second half of 2026, subject to customary closing conditions, including approvals from JATT II shareholders and regulators. Upon closing, the combined company expects to receive $285 million in gross proceeds. Proceeds will be funded through a combination of $60 million held in a trust account by JATT II, assuming no redemptions by JATT II's public shareholders, and an oversubscribed $225 million concurrent private investment in public equity (PIPE) of common stock at $10 per share. The PIPE is led by founding investor Access Biotechnology and includes participation from Bain Capital Life Sciences, Deep Track Capital, RA Capital Management, Janus Henderson Investors, Vianti Capital, Farallon Capital Management, and other leading health-care-dedicated investors and mutual funds.

The combined company will operate as Talawar Therapeutics and is expected to trade on the Nasdaq Capital Market under the ticker symbol "TLWR." Available cash at closing is anticipated to fund the advancement of TALA-125, a novel bispecific antibody for atopic dermatitis, with clinical entry expected in the first quarter of 2027, through a Phase 2b proof-of-concept study data readout in the second half of 2028.

The multioffice Greenberg Traurig team is led by Alan I. Annex, vice chair of the firm and senior chair of the firm's Global Corporate Practice, New York Corporate Shareholder Adam S. Namoury and Capital Markets Shareholder Anthony Zangrillo, and New York Corporate Associates Ricardo Crispim Leite, Stefano de Conciliis, Benjamin Cohen, John Diamandis, and Christina A. Revilla Chacon.

Other team members include Shareholders Mindy B. Leathe in the Tax Practice in Miami, Whitney Bly Edwards, Ph.D. in the Labor & Employment Practice in Atlanta, Justin P. Hedge in the Antitrust & Competition Practice in Washington, D.C., Rebecca Tracy Rotem in the Corporate Practice in Washington, D.C., and David M. Greenberg in the Technology, Media, & Telecommunications Practice in New York. The team also includes Of Counsel Tzy-Ying (Sandy) Chiu in the Intellectual Property & Technology Practice in New York, Associate Sukhdeep S. Gill in the Intellectual Property & Technology Practice in Philadelphia, and Shareholders James Maynor and Robert D. Simon in the Tax Practice in Northern Virginia.